Post Discharge Trial to Enhance Immunity in Severely Malnourished Children

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-36
SponsorInternational Centre for Diarrhoeal Disease Research, Bangladesh

About this trial

The goal of this study is to evaluate the efficacy of microbiota-directed food in comparison to zinc with micronutrient powder and Khichuri on changes in circulating immune cells (monocytes, T cells, B cells, and NK cells) in malnourished children after recovery from acute infection.

The study aims to answer the research question:

Does microbiota-directed food (MDF) compared to zinc with micronutrient powder (MNP) and Khichuri therapy enhance immunity in children with severe acute malnutrition? The researcher will compare the effectiveness of microbiota-directed food (MDF) versus zinc with micronutrient powder (MNP) and Khichuri therapy to see if MDF enhances immunity in severely malnourished children.

Severely malnourished children will:

* Receive microbiota-directed food (MDF) or zinc with micronutrient powder (MNP) and Khichuri every day for 12 weeks. * Phenotyping of circulating immune cells (NK cells, T cells, B cells) will be conducted using flow cytometry and fluorescence-activated cell sorting techniques.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Children aged 6 months to 36 months, and

Severe acute malnutrition as evident by weight-for-length z-score (WLZ) < -3 and or mid-upper arm circumference (MUAC) < 11.5 cm, and or edema of both feet, and

Completed the acute phase management for SAM and stayed at NRU for 7±4 days, with no medical complications, e.g. lethargic/unconscious, convulsions, unable to drink, persistent vomiting, respiratory distress.

Residing within the Dhaka district.

Disqualifiers

WLZ ≥ -3 or MUAC ≥11.5 cm.

Presence of lethargy/unconsciousness, convulsions, unable to drink, persistent vomiting, respiratory distress.

Participants who receive multiple courses of antibiotic (>2 courses during acute phase) treatment for a prolonged period (>14 days).

Persistent diarrhea (≥14 days).

Trial design

Design model

Parallel

Treatments tested in this trial

  • Microbiota-directed food

    Dietary supplement

    MDF can modulate the gut microbiota and enhance host immunity, growth, and development in malnourished children. Each sachet of MDF (100 gm) provides approximately 500 kcal.

  • Khichuri

    Dietary supplement

    Khichuri is a home-based nutritious food with high energy and protein. This arm also contains zinc (10 gm/day), micronutrient powder, and an egg daily.

Treatment groups

150 Participants
are divided into 2 treatment groups
Group A: Microbiota-directed foodExperimental treatment 1 intervention
Group B: KhichuriActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

NK cells

Differences in the proportion and activity of circulating NK cells between the groups 12 weeks after the intervention, measured by flow cytometry/fluorescence-assisted cell sorter (FACS).

Time frame
12 weeks

Secondary outcomes

1

Circulating immune cells

Differences in the proportion of circulating immune cells (NK cells, T cells, B cells) before and after the interventions

Time frame
12 weeks
2

Cytokines and chemokines

Differences in the levels of pro-inflammatory and anti-inflammatory cytokines and chemokines in circulation, which can provide insights into the functional status of immune cells

Time frame
12 weeks
3

Micro biocidal capacity

Differences in the micro biocidal capacity (oxidative burst) of neutrophils and monocytes.

Time frame
12 weeks
4

Rate of weight gain

Rate of weight gain between the intervention groups over the 12-weeek intervention period.

Time frame
12 weeks

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

International Centre for Diarrhoeal Disease Research, Bangladesh

Lead sponsor

Washington University School of Medicine

Collaborator

This trial is not recruiting at the moment. You can still explore other options: